This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kahaly, G. Articles by Hommel, G. Search for Related Content PubMed PubMed Citation Articles by Kahaly, G. Articles by Hommel, G.

Randomized, Double Blind, Placebo-Controlled Trial of Low Dose Iodide in Endemic Goiter

Departments of Endocrinology/Metabolism, Pathology (H.P.D.), and Medical Statistics (G.H.), Gutenberg University Hospital, Mainz, Germany

Address all correspondence and requests for reprints to: Professor George J. Kahaly, University Hospital, Building 303, Mainz 55101, Germany.

Iodine (I) is essential for normal thyroid function, and the majority of subjects tolerate a wide range of dietary levels. However, a subset of individuals upon exposure to normal or elevated levels of I develop thyroid dysfunction and autoimmunity. In this double blind trial, we evaluated efficacy and tolerability of low dose I in adults with euthyroid, diffuse, endemic goiter. Sixty-two subjects were randomly assigned I (0.2 mg/day) or placebo for 12 months. After termination of therapy, both groups were followed for a further 6 months. Thyroid sonography and determinations of thyroid-related hormones, urinary I excretion per 24 h, and thyroid antibodies were carried out at baseline and at 3, 6, 9, 12, 15, and 18 months. Markedly elevated urinary I values were found during therapy in subjects receiving I (32 at baseline vs. 213 µg/24 h at 12 months; P = 0.0001) compared to placebo (34 and 33 µg/24 h, respectively; P < 0.0001 vs. I). I substantially reduced thyroid volume (29 vs. 18 mL at 12 months; -38%; P = 0.0001), and at 18 months, the therapeutic effect was sustained. In the placebo group, no significant changes were observed. High microsomal and thyroglobulin autoantibody titers were present in 3 of 31 (9.7%) subjects receiving I, and I-induced hypo- and hyperthyroidism developed in 2 and 1, respectively. Fine needle biopsy revealed marked lymphocytic infiltration in all 3 cases. After withdrawal of I, thyroid dysfunctions spontaneously remitted, and antibody titers as well as lymphocytic infiltration decreased markedly. Follow-up of these 3 subjects for an additional 2 yr showed normalization of antibody titers in 2. Thus, among subjects with endemic goiter, low dose I successfully normalized thyroid volume and body I supplementation; nevertheless, reversible I-induced thyroid dysfunctions and autoimmunity were observed in nearly 10% of the subjects.

This article has been cited by other articles:

				K. B. Markou, P. Paraskevopoulou, K. S. Karaiskos, M. Makri, N. A. Georgopoulos, G. Iconomou, C. Mengreli, and A. G. Vagenakis Hyperthyrotropinemia during Iodide Administration in Normal Children and in Children Born with Neonatal Transient Hypothyroidism J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 617 - 621. [Abstract] [Full Text] [PDF]

				J. T. Dunn Guarding our Nation's Thyroid Health J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 486 - 488. [Full Text] [PDF]

				P. L Jooste, M. J Weight, and C. J Lombard Short-term effectiveness of mandatory iodization of table salt, at an elevated iodine concentration, on the iodine and goiter status of schoolchildren with endemic goiter1 Am. J. Clinical Nutrition, January 1, 2000; 71(1): 75 - 80. [Abstract] [Full Text] [PDF]

				J. T. Dunn What's Happening to Our Iodine? J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3398 - 3400. [Full Text]